In vivo molecular targeted radiotherapy

Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage

Radioisotopes that emit electrons (beta particles), such as radioiodine, can effectively kill target cells, including cancer cells. Aqueous ³²P[PO₄] is a pure beta-emitter that has been used for several decades to treat non-malignant human myeloproliferative diseases. ³²P[PO₄] was directly compared to a more powerful pure beta-emitter, the clinically important ⁹⁰Y isotope. In vitro, ³²P[PO₄] was more effective at killing cells than was the more powerful isotope ⁹⁰Y (P ≤ 0.001) and also caused substantially more double-stranded DNA breaks than did ⁹⁰Y. In vivo, a single low-dose intravenous dose of aqueous elemental ³²P significantly inhibited tumor growth in the syngeneic murine cancer model (P ≤ 0.001). This effect is exerted by direct incorporation into nascent DNA chains, resulting in double-stranded breakage, a unique mechanism not duplicatable by other, more powerful electron-emitting radioisotopes. ³²P[PO₄] should be considered for human clinical trials as a potential novel anti-cancer drug.

A review on various targeted anticancer therapies

Translational oncology aims to translate laboratory research into new anticancer therapies. Contrary to conventional surgery, chemotherapy, and radiotherapy, targeted anticancer therapy (TAT) refers to systemic administration of drugs with particular mechanisms that specifically act on well-defined targets or biologic pathways that, when activated or inactivated, may cause regression or destruction of the malignant process, meanwhile with minimized adverse effects on healthy tissues. In this article, we intend to first give a brief review on various known TAT approaches that are deemed promising for clinical applications in the current trend of personalized medicine, and then we will introduce our newly developed approach namely small molecular sequential dual targeting theragnostic strategy as a generalized class of TAT for the management of most solid malignancies, which, after optimization, is expected to help improve overall cancer treatability and curability.